Evidence map›Paper›PMID 21854283›Full record

ArticleThe American journal of drug and alcohol abuse2011

Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection.

Jennifer Sharpe Potter, Dennis M Donovan, Roger D Weiss, John Gardin, Robert Lindblad, Paul Wakim, Dorian Dodd

Abstract read
In one paragraph

Article in The American journal of drug and alcohol abuse, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Relation of study design to recruitment and retention in CTN trials.The American journal of drug and alcohol abuse · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jennifer Sharpe PotterDivision of Alcohol and Drug Abuse, Department of Psychiatry, School of Medicine, University of Texas Health Science Center, San Antonio, 78232, USA. potterjs@uthscsa.edu
Dennis M Donovan
Roger D Weiss
John Gardin
Robert Lindblad
Paul Wakim
Dorian Dodd

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
OREGON NODE - NATIONAL CLINICAL TRIALS NETWORKU10DA013036 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCCARTY, DENNIS · 1999 to 2010
$18.5M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
Treatment of Opioid Dependence and Chronic PainK23DA022297 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI POTTER, JENNIFER SHARPE · 2008 to 2012
$878k
NCRR NIH HHS UL1 RR025014NIDA NIH HHS K23 DA022297NIDA NIH HHS K24 DA022288NIDA NIH HHS U10 DA013036NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA015831NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

backgroundThe importance of conducting substance use disorder treatment research in real-world settings is now well recognized. While this approach to clinical trials research offers a variety of benefits, challenges also arise. Selecting high-quality sites to participate is critical to recruitment, retention, and overall trial performance when conducting multi-site, community-based clinical trials of treatments for substance use disorders.

objectivesOver the past 10 years, the National Institute on Drug Abuse-sponsored National Drug Abuse Treatment Clinical Trials Network (CTN) has strived to conduct high-quality, well-managed clinical trials. This includes developing methods for site selection to be used by investigators conducting CTN trials.

methodsWe review site selection strategies from two community-based multi-site clinical trials conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network.

resultsIssues relevant to site selection include the clinical trial design, availability of appropriate clinical population, and organizational attributes of potential clinical research sites. Site selection strategies include reviewing regional epidemiologic data, collecting standard site selection surveys, evaluating clinic data on existing patient populations, and site selection interviews and visits.

conclusionThis article describes considerations for selecting research sites and identifies specific strategies to employ when selecting community-based sites for participation in clinical trials.

Indexed as

Clinical Trials as TopicCommunity Health ServicesData CollectionHumansMulticenter Studies as TopicNational Institute on Drug Abuse (U.S.)Patient SelectionResearch DesignSubstance-Related DisordersUnited States

Identifiers

PMID21854283
PMCPMC3160724

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.